News

Landos Biopharma Announces Publication of Results from Non-clinical Toxicity Studies Further Characterizing the Safety Profile of BT-11

Read More

Landos Biopharma Announces Publication Supporting Novel, Dual Mechanism of Action for BT-11 in Models of IBD

Read More

Dr. Bassaganya-Riera, Landos Chairman & CEO, Provides Corporate and Clinical Update

Read More

Landos Biopharma Announces Final Safety Results from Phase I Study of BT-11 in Healthy Volunteers

Read More

Landos Biopharma at BIO Investor Forum

Read More

First Human Dosing of BT-11 Announced

Read More